Business Wire

CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at ACC

Del

CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company will present fundamental new insights into the coronary microcirculation during the annual meeting of the American College of Cardiology (ACC) in Orlando, FL, March 10-12, 2018.

CorFlow has since its foundation in June 2016 worked to document that the Controlled Flow Infusion (CoFITM) technology is able to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time. Microvascular obstruction (MVO) affects more than half of the acute heart attack patients and is an independent predictor for complications including heart failure which constitutes a high cost burden for the world-wide health care system. To address this large unmet medical need in interventional cardiology, CorFlow has developed an in-vivo model which reproducibly creates MVO in an occlusion-reperfusion model with very low complication rates. Using this in-vivo model, the CoFITM technology was used to measure real-time dynamic microvascular resistance (dMVR) in the coronary circulation and these dMVR values were correlated to post-procedure contrast enhanced magnetic resonance imaging (MRI) and histology. A correlation between the procedural CoFITM dMVR values and post-procedural MRI will enable treatment of MVO before the patients leave the cathlab and potentially reduce the complication rates for severe heart attack patients.

In a comment, Dr. Renu Virmani, an internationally renowned cardiovascular pathologist and co-author of the histology poster, stated: "These findings suggest that the fundamental effects of a human heart attack have to be reconsidered. Our findings show that MVO in acute heart attacks can be created without the presence of thrombi. The results furthermore show that minute reductions in coronary volume flow causes an exponential collapse of the coronary microcirculation and that epicardial revascularization alone is not sufficient to open the collapsed coronary microcirculation. If these findings hold true in our upcoming investigations, we will have to fundamentally rethink the comprehensive treatment of an acute heart attack with attention to the microvasculature as well as the major epicardial vessels."

Jon H. Hoem, CorFlow's CEO and co-Founder, commented: "We are very pleased that our in-vivo results have been accepted for publication during the important ACC conference and look forward to discuss these results with cardiologists attending the conference."

The data from the CorFlow non-clinical trials will be used in the upcoming submissions for the CorFlow MOCA I (MVO with CoFI™ System Assessment I) First-in-Man clinical trial.

Contact information

CorFlow Therapeutics AG
Jon H. Hoem, +41 79 606 2 902
jhoem@corflow-therapeutics.ch

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer13.12.2018 17:46Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include rucaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. EC approval is anticipated in the first quarter of 2019. Once approved, Rubraca’s indication will expand beyond its initial Marketing Authorization in Europe granted in May 2018 for adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum

Dole Food Company Sells Fresh Cut Business in Sweden and Finland13.12.2018 17:00Pressemelding

Dole Food Company, Inc., announced today an agreement to sell Saba Fresh Cuts AB and Saba Fresh Cuts OY to BAMA International. Saba Fresh Cuts AB—with production facility in Helsingborg Sweden—and Saba Fresh Cuts OY—with production facility in Espoo Finland—are producers of washed and ready-to-eat salads. The companies prepare and sell various fresh-cut salads and vegetables to the retail and foodservice industry in Sweden, Denmark, Finland, Germany and the Baltic States. The sale of Saba Fresh Cuts AB was a necessary condition of the European Commission’s approval of the investment by Total Produce into Dole in July 2018. “I am very pleased with the outcome of this sale in meeting the EU’s requirement,” said Mr. Johan Linden, President and Chief Executive Officer of Dole Food Company, “and I am confident that Saba Fresh Cuts will be in good hands under BAMA’s ownership.” "We are pleased to announce this agreement with Dole for Saba Fresh Cuts. Convenience products and ready-to-eat sal

Thales and Gemalto Are Granted Regulatory Clearance by the Commerce Commission in New Zealand13.12.2018 16:00Pressemelding

Regulatory News: Reference is made to the joint press release by Thales (Euronext Paris: HO) and Gemalto (Euronext Amsterdam and Paris: GTO) dated 27 March 2018 in relation to the launch of the recommended all-cash offer by Thales for all the issued and outstanding shares of Gemalto (the “Offer”), the publication of the Offer Document, and the joint press release of Thales and Gemalto dated 10 August 2018 in relation to the further extension of the Acceptance Period. Terms not defined in this press release will have the meaning as set forth in the Offer Document. Thales and Gemalto announce today that they have received merger control Regulatory Clearance from the Commerce Commission in New Zealand, following Thales’s commitment to divest its general purpose hardware security modules (GP HSM) business globally1 to a suitable purchaser. This clearance is effective immediately. Together with the antitrust clearances obtained in China, Israel, South Africa, Turkey, and for the European Un

Hurricane Electric Becomes First Internet Backbone to Connect to 200 Internet Exchanges around the Globe13.12.2018 15:37Pressemelding

Hurricane Electric, the world’s largest IPv6-native Internet backbone, today announced that it is the first Internet backbone in the world to connect to over 200 unique Internet exchanges. As an early leader in the switch to IPv6, Hurricane Electric now connects to the largest number of networks on the planet for both IPv6 and IPv4 and has been at the forefront of providing high-speed Internet connectivity to organizations throughout the world using:100GE (100 Gigabit Ethernet), 10GE (10 Gigabit Ethernet), and GigE (1 Gigabit Ethernet) connections. As a result of the improved connectivity with these 200 exchanges, customers receive the benefit of lower latency, higher throughput and increased fault tolerance. This reliable connectivity is especially important as global IP traffic continues to increase – Cisco’s Visual Networking Index: Forecast and Trends, 2017–2022 predicts that annual global IP traffic will reach 4.8 zettabytes (ZB) per year by 2022, or 396 exabytes (EB) per month, t

The World's Largest Heritage and Culture Festival to Begin With the Slogan Janadria 33 Faithfulness and Loyalty13.12.2018 15:15Pressemelding

With the support and under the patronage of the Custodian of the Two Holy Mosques King Salman bin Abdulaziz, the 33rd Edition of the National Festival of Heritage and Culture will be held in Janadria for 21 days from Thursday 20th December 2018 to Wednesday 9th January 2019. Organized by the Saudi Ministry of National Guard, the festival is part of the efforts to intensify attention to Saudi heritage, expose it regionally and globally and to promote dialogue among cultures and civilizations on the level of people and nations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005472/en/ The Custodian of the Two Holy Mosques King Salman bin Abdulaziz (Photo: AETOSWire) Janadria is the largest Saudi cultural festival that simulates the history, present and future of Saudi Arabia and the largest event of its kind in the region. Since 1985, it has witnessed extensive Saudi participation, a growing Arab and Gulf presence and an

PPG to Invest in Automated Dispense Cell Manufacturing for Automotive Parts and Accessories13.12.2018 14:32Pressemelding

PPG (NYSE: PPG) today announced that it is increasing its investment in automated dispense cell manufacturing of paint and related coatings for the automotive parts and accessories decorative (APAD) space. Financial details are not being disclosed. Dispense cell technology enables PPG to dramatically accelerate production and approval of paint batches for vehicle original equipment manufacturers (OEMs) and component suppliers. The technology allows coatings components to be automatically drawn from storage vats in the correct proportions and mixed directly in their shipping containers, vastly simplifying and increasing the efficiency of the coatings manufacturing process. PPG recently launched an APAD dispense cell operation at its San Juan del Rio, Mexico, coatings facility and will begin production on an additional cell in 2019 in Sriperumbudur, India. These cells are in addition to PPG’s recent APAD investments in Germany and Russia and the dispense cells already online at the Compa